The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1671
ISSUE1671
March 6, 2023
Elacestrant (Orserdu) for Advanced or Metastatic Breast Cancer
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Elacestrant (Orserdu) for Advanced or Metastatic Breast Cancer
March 6, 2023 (Issue: 1671)
The FDA has approved elacestrant (Orserdu –
Stemline), an oral estrogen receptor antagonist, for
treatment of estrogen receptor (ER)-positive, human
epidermal growth factor receptor 2 (HER2)-negative,
estrogen receptor 1 (ESR1)-mutated advanced...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.